Jean-Yves Reginster

Prof. Jean-Yves Reginster

University of Liège, Liège, Wallonia, Belgium
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in The Lancet
Verified
Journal Article
Closed access
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster
RDRita Deroisy
Rita Deroisy
LRLucio C Rovati
Lucio C Rovati
RLRichard L Lee
Richard L Lee
ELEric Lejeune
Eric Lejeune
CGChristiane Gossett
Christiane Gossett

1 February 2006 in Bone
Verified
Journal Article
Closed access
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster
NBNansa Burlet
Nansa Burlet

1 May 2005 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster
ESE. Seeman
E. Seeman
MVM. C. De Vernejoul
M. C. De Vernejoul
SAS. Adami
S. Adami
JCJ. Compston
J. Compston
PMP. J. Meunier
P. J. Meunier
Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to assess its efficacy and safety in preventing nonvertebral fractures also. Strontium ranelate (2 g/d) or placebo were randomly allocated to 5091 postmenopausal women with osteoporosis in a double-blind placebo-controlled 5-yr study with a main statistical analysis over 3 yr of treatment. In the entire sample, relative risk (RR) was reduced by 16% for all nonvertebral fractures (P = 0.04), and by 19% for major fragility fractures (hip, wrist, pelvis and sacrum, ribs and sternum, clavicle, humerus) (P = 0.031) in strontium ranelate-treated patients in comparison with the placebo group. Among women at high risk of hip fracture (age > or = 74 yr and femoral neck bone mineral density T score < or = -3, corresponding to -2.4 according to NHANES reference) (n = 1977), the RR reduction for hip fracture was 36% (P = 0.046). RR of vertebral fractures was reduced by 39% (P < 0.001) in the 3640 patients with spinal x-rays and by 45% in the subgroup without prevalent vertebral fracture. Strontium ranelate increased bone mineral density throughout the study, reaching at 3 yr (P < 0.001): +8.2% (femoral neck) and +9.8% (total hip). Incidence of adverse events (AEs) was similar in both groups. This study shows that strontium ranelate significantly reduces the risk of all nonvertebral and in a high-risk subgroup, hip fractures over a 3-yr period, and is well tolerated. It confirms that strontium ranelate reduces vertebral fractures. Strontium ranelate offers a safe and effective means of reducing the risk of fracture associated with osteoporosis.

5 October 2016 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
CBCharlotte Beaudart
Charlotte Beaudart
EMEugène McCloskey
Eugène McCloskey
Olivier BruyèreOlivier Bruyère
Olivier Bruyère
MCMatteo Cesari
Matteo Cesari
RYRolland Yves
Rolland Yves
CCCyrus Cooper
Cyrus Cooper
Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice. This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations. This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions. Development of a number of pharmacological interventions is also in progress. Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.

2 February 2018 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
MCMatteo Cesari
Matteo Cesari
ICIslene Araujo de Carvalho
Islene Araujo de Carvalho
JTJotheeswaran Amuthavalli Thiyagarajan
Jotheeswaran Amuthavalli Thiyagarajan
CCCyrus Cooper
Cyrus Cooper
FMFinbarr C Martin
Finbarr C Martin
JBJohn R Beard
John R Beard
Healthy ageing can be defined as “the process of developing and maintaining the functional ability that enables wellbeing in older age”. Functional ability (i.e., the health-related attributes that enable people to be and to do what they have reason to value) is determined by intrinsic capacity (i.e., the composite of all the physical and mental capacities of an individual), the environment (i.e., all the factors in the extrinsic world that form the context of an individual’s life), and the interactions between the two. This innovative model recently proposed by the World Health Organization has the potential to substantially modify the way in which clinical practice is currently conducted, shifting from disease-centered toward function-centered paradigms. By overcoming the multiple limitations affecting the construct of disease, this novel framework may allow the worldwide dissemination of a more proactive and function-based approach toward achieving optimal health status. In order to facilitate the translation of the current theoretical model into practice, it is important to identify the inner nature of its constituting constructs. In this article, we consider intrinsic capacity. Using the International Classification of Functioning, Disability and Health (ICF) framework as background and taking into account available evidence, five domains (i.e., locomotion, vitality, cognition, psychological, sensory) are identified as pivotal for capturing the individual’s intrinsic capacity (and therefore also reserves) and, through this, pave the way for its objective measurement.

1 March 2024 in Age and Ageing
Verified
Journal Article
Open access
PDF file
BKBen Kirk
Ben Kirk
PCPeggy Cawthon
Peggy Cawthon
HAHidenori Arai
Hidenori Arai
JAJosé Alberto AVILA-FUNES
José Alberto AVILA-FUNES
RBRocco Barazzoni
Rocco Barazzoni
ACAlfonso J Cruz-Jentoft
Alfonso J Cruz-Jentoft
Importance: Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists. Objective: The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia. Design: The GLIS steering committee was formed in 2019–21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70–80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached. Results: 107 participants (mean age: 54 ± 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on ‘general aspects of sarcopenia’ (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on ‘components of sarcopenia’ (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on ‘outcomes of sarcopenia’ (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as ‘components of sarcopenia’, whereas impaired physical performance was accepted as an ‘outcome’ rather than a ‘component’ of sarcopenia. Conclusion and relevance: The GLIS has created the first global conceptual definition of sarcopenia, which will now serve to develop an operational definition for clinical and research settings.